ANCON1 ANEMIA (FA) is an autosomal recessive disease characterized by various birth defects, progressive bone marrow failure, and a markedly increased incidence of malignancies, most notably acute myeloid leukemia. Cells cultured from FA patients exhibit an increased level of spontaneous chromosomal aberrations and are hypersensitive to the chromosome-breaking and killing effects of cross-linking agents, such as mitomycin C ("C) and diepoxybutane (DEB).',' FA is genetically heterogeneous: 4 complementation groups (FA-A through FA-D) have been distinguished based on somatic cell hybridization studies,3 implying that at least 4 genes cooperate to support normal hematopoiesis in nonaffected individuals.
The gene for group C (FAC; see Lehmann et a14 for nomenclature) is the only FA gene cloned thus far.' FAC codes for a cytoplasmically localized6,' protein with unknown function. Six disease-associated sequence variations have so far been found in the FAC gene, one of which, IVS4+4AT, accounts for the majority of FA cases in Ashkenazy Jews.839 In non-Jewish people, the proportion of FA patients belonging to complementation group C is estimated to be 8%, based on the disease-associated segregation of polymorphic markers linked to FAC at 9q22.3"; however, prevalences may vary with geographic region or ethnical structure of the populations studied.
The importance of using complementation analysis for the genetic classification of FA patients is several-fold. First, complementation analysis is a powerful means to discover new FA genes and would permit an estimate of FA subtype prevalences in the human population even before the corresponding genes have been isolated. In addition, classification of FA families by complementation analysis would allow positional cloning of FA genes through linkage analysis. Furthermore, complementation analysis can be a critical tool in ascertaining the pathogenic status of sequence alterations found in FAC by mutation screening methods." Finally, in view of upcoming clinical trials designed to correct the bone marrow failure in FA patients by gene therapy,' complementation analysis is an important means to select patients who are eligible for such treatment.
Notwithstanding its importance, complementation analysis has sofar been limited to only 7 patients. DuckworthRysiecki et all2 used a hypoxanthine, aminopterine, and thymidine (HAT)-sensitive (hprt-), ouabain-resistant derivative of an FA lymphoblastoid cell line (HSC720T) as a fusion donor, which permitted selective outgrowth of heterokaryotic hybrids by HAT + ouabain selection. MMC sensitivity profiles of the hybrid cell lines obtained upon fusion with 6 FA lymphoblast lines indicated that 3 were identical to HSC720T (defined as group A), whereas the remaining 3 were non-A.'2 Subsequently, Strathdee et a 1 3 succeeded in introducing drug-resistance markers into each of these 3 non-A cell lines by transfection with pSV2neo (conferring G418 resistance) or pSV2hph (for hygromycin resistance), which allowed hybrid selection by having both drugs present simultaneously during outgrowth of fusion mixtures. Using this system, all possible combinations of the 3 non-A lines resulted in "C-resistant hybrid cell lines, strongly suggesting that each cell line represented a separate complementation group, designated FA-B, FA-C, and FA-D. ' The method used by Strathdee et 
MATERIALS AND METHODS
Patients and cell lines. Epstein-Barr virus-immortalized cell lines were established from blood samples obtained after informed consent was given by patients living in Germany and The Netherlands and diagnosed as having FA on the basis of clinical symptoms in combination with hypersensitivity to cross-linking agents, as determined in a standard chromosomal breakage test. The FA diagnosis of patient 93W130, assigned here to a new complementation group FA-E, was based on the following data. The (male) patient was born from a consanguineous marriage with a low birth weight, microcephaly, hypoplasia of his right thumb, and retarded bone age. At 3.5 years of age, the patient developed thrombocytopenia followed by pancytopenia; he died at 6.3 years of age from pulmonary hemorrhage. Cytogenetic analysis performed at 3 years of age showed high spontaneous chromosomal breakage (0.37 breakslcell) and hypersensitivity to DEB (100% aberrant metaphases after 48 hours of treatment with 0.1 pg/mL, with an average of >3.5 breakdcell; normal controls exhibited no significant effect from this treatment). A detailed account of the clinical and cytogenetic features of patient 93VU130 will be published elsewhere (Wegner et al, manuscript in preparation).
Cell culture. Culture medium was RPM1 1640 plus 1 mmol/L glutamine (GIBCO, Grand Island, NY) supplemented with 1 mmoY L sodium pyruvate and 10% fetal calf serum (GIBCO).
Complementation analysis. The fusion donor cell lines used to determine the FA-subtype in lymphoblasts from unclassified FA patients were HSC720T (FA-A), HSC230NT-spl (FA-B), HSC536NT-E6 (FA-C), and HSC62NT-sp8 (FA-D). HSC720T cells (OT indicating ouabain and 6-thioguanine resistance, respectively), representing complementation group A, were used previously to distinguish group-A from non-A patients." From the three cell lines that represent groups B, C, and D,' NT derivatives were prepared, which are resistant to G418 (due to an integrated pSV2Neo pla~mid)~ and 6-thioguanine (due to a hprt-mutation). hprt-mutants were collected either without prior mutagen treatment (HSC230NT-spl and HSC62NT-sp8) or after 16 hours of treatment with 100 pmoll L ethyl methane sulphonate and 12 days of expression time (HSC536NT-E6). Clones were allowed to develop over a 2-week period in 96-well microtiter plates seeded with 40,000 cells per well with medium containing 5 pg/mL 6-thioguanine. Plates were kept under an atmosphere containing 0.1% Oz (balanced with 5% COz and N,) for the first week and 20% Oz for the second week. Cloning efficiencies were typically 25%. The hprt-mutation is a recessive marker confemng sensitivity to medium with HAT (GIBCO), which blocks de novo synthesis of purines and kills hprt-cells that are unable to use the salvage pathway of purine synthesis. Heterokaryons survive in medium containing G418 plus HAT, whereas monokaryons and homokaryons are killed.
Cell fusion and growth inhibition tests. Twenty million lymphoblasts from an unclassified FA patient were mixed with 20 million lymphoblasts from 1 of the 4 reference cell lines, resuspended in serum-free (SF) medium, and divided in 4 equal portions for 4 parallel fusion experiments. After centrifugation, cell fusion was induced by gently resuspending the cells in 1 mL of a solution containing 50% polyethylene glycol (type IOOO; Sigma, St Louis, MO) in SF medium. After 1 minute of standing at room temperature, 4 mL of SF medium was added, followed after another 2 minutes by another 4 mL. After 30 minutes at room temperature, the cells were washed by centrifugation and resuspended in complete medium. After 48 hours at 37°C selection of hybrids was started by adding medium containing HAT (GIBCO) plus ouabain (1 pmoVL; fusions with HSC720T) or HAT plus G418 (400 pg/mL; fusions with the NT-derivative cell lines). Hybrids were authenticated by checking the presence of the minisatellite VNTR marker D1S80 variants from both parental cell lines. Cross-linker sensitivity of cell lines and hybrids was assessed in a growth inhibition assay.'? Cultures were initiated at 5 X 104/mL in multiple 5-mL aliquots containing various concentrations of MMC (0 to 100 nmoVL) and al- Table 3 .
Abbreviation: ND, not done. lowed to grow for 5 to 10 days until the cells not exposed to MMC had undergone at least 3 population doublings; all parallel cultures were then counted with a Coulter counter (Coulter, Hialeah, F%). Hybrids were grown in the continued presence of HAT plus ouabain (1 pmoVL) or G418 (400 pg/mL) in addition to various concentrations of MMC. Because lack of complementation could theoretically be due to (random) loss of the complementing chromosomes from either fusion partner, noncomplementation was confirmed in multiple independent fusions.
Chromosomal breakage analysis. Chromosomal breakage was evaluated in untreated lymphoblasts and after treatment with 50 nmol/L MMC for 24 hours. From each culture at least 50 metaphases were scored, from coded slides, for chromosome number and the presence of unstable structural chromosomal aberrations. Only chromatid-type aberrations were quantified to avoid interference from stable alterations that are commonly present in human lymphoblasts. Chromatid interchanges were counted as two break events. Figure 1 illustrates the classification of patient 92VU001 as belonging to group FA-C, based on the persistence of the FA phenotype (MMC sensitivity) when fused with the reference FA-C cell line HSC536NT-E6 and complete correction of the sensitive phenotype when fused with the FA-A, -B and -D reference cell lines. As summarized in Table  l , Table  1 ). Two additional experiments confirmed this conclusion. First, the results obtained on MMC cytotoxicity were confirmed with two other cross-linking agents for which FA cells are known to be hyper~ensitive,'~ namely DEB and cisplatinum (Table  2) . Second, as summarized in Table 3 , MMC-induced chromosomal breakage was complemented in all hybrid cell lines obtained after fusion with 93VU130-L cells, whereas hybrids with 92VUOO1-L cells (classified as FA-C) showed significant MMC-induced breakage only in combination with the reference FA-C cell line. Thus, these results strongly support the hypothesis that patient 93VU130 represents a new complementation group, FA-E.
RESULTS

DISCUSSION
Our results indicate that FA patients can be classified according to their genetic subtype by complementation analysis using new genetically marked FA reference cell lines. The reliability of the analysis is implied by the finding that all 4 patients assigned to group C by complementation were found to have mutations in the corresponding gene, FAC. Patient 93VU130 was assigned to a new complementation group FA-E, based on the correction of manifestations of the FA defect that are commonly seen at the cellular level, ie, hypersensitivity to cross-linkers, both in terms of growth inhibition and induced chromosomal aberrations. Because the FA diagnosis for this patient, assessed on the basis of clinical phenotype and standard cytogenetic analysis (see Materials and Methods), was beyond doubt, our results strongly indicate that a minimum of 5 genes, when defective, can cause FA. Spontaneous chromosomal instability is a commonly observed phenomenon in FA cell cultures. Table 3 shows considerable variation in the level of spontaneous aberrations, ranging from 0.1 to 0.86 breakskell (average, 0.4) for the parental FA cell lines and 0.12 to 0.68 breakskell (average, 0.3) in the hybrids, suggesting that background instability levels are not corrected down to the level seen in diploid control cells. We have no explanation for this apparent lack of correction, except to suggest that it may be related to specific characteristics of hybrid cell lines. However, because the spontaneous instability levels in the fusions involving 92VUO01-L cells, whose FA-C assignment was unambiguous on the basis of complementation as well as mutation analysis, also did not seem to be corrected, the data apparently do not contradict our conclusion concerning the classification of patient 93VU130.
For non-C patients, the results confirm the reported level of genetic heterogeneity in that new patients were identified who apparently belonged to complementation groups A (7 patients) and D (1 patient); none of the patients analyzed so far could be classified as FA-B, suggesting that FA-B patients may not be present in the population of FA patients sampled for this study. Our data together with those on the 7 patients typed earlie8-7" indicate that FA-A is the most prevalent group among ethnically and clinically unselected FA patients from North AmericdCanada and Europe (55%; 95% confidence interval, 32% to 77%). The numbers for the other groups are still too small to derive a reliable estimate of their prevalences.
In principle, complementation analysis by cell fusion would allow the genetic classification of many FA patients; however, the method has several limitations that make it less suitable for screening on a large scale. First, we find that blood samples from approximately 20% of FA patients yield cell lines that fail to exhibit MMC sensitivity. Such genetically reverted cell lines evidently cannot be used for complementation studies. Second, the procedure requires specially trained laboratory personnel and is time-consuming, ie, 6 to 8 weeks to establish a cell line and another 6 to 8 weeks for each cell fusion to be performed and analyzed. Therefore, screening for specific mutations in the FAC and linkFor personal use only. on April 3, 2017. by guest www.bloodjournal.org From age analysis of polymorphic markers flanking the FAC gene" in a patient's family are first-choice methods to assess whether a patient belongs to group FA-C or not. However, until the genes for the other complementation groups have been cloned, complementation analysis is currently the only available method for the genetic classification of non-C FA patients.
